|
1
|
Zhang J, Ding L, Holmfeldt L, Wu G,
Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M, et
al: The genetic basis of early T-cell precursor acute lymphoblastic
leukaemia. Nature. 481:2905–163. 2012. View Article : Google Scholar
|
|
2
|
Holmfeldt L, Wei L, Diaz-Flores E, Walsh
M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen
SC, et al: The genomic landscape of hypodiploid acute lymphoblastic
leukemia. Nat Genet. 45:242–52. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paulsson K, Lilljebjörn H, Biloglav A,
Olsson L, Rissler M, Castor A, Barbany G, Fogelstrand L, Nordgren
A, Sjögren H, et al: The genomic landscape of high hyperdiploid
childhood acute lymphoblastic leukemia. Nat Genet. 47:672–676.
2015. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qian M, Zhang H, Kham SK, Liu S, Jiang C,
Zhao X, Lu Y, Goodings C, Lin TN, Zhang R, et al:
Whole-transcriptome sequencing identifies a distinct subtype of
acute lymphoblastic leukemia with predominant genomic abnormalities
of EP300 and CREBBP. Genome Res. 27:185–195. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mullighan CG, Zhang J, Kasper LH, Lerach
S, Payne-Turner D, Phillips LA, Heatley SL, Holmfeldt L,
Collins-Underwood JR, Ma J, et al: CREBBP mutations in relapsed
acute lymphoblastic leukaemia. Nature. 471:235–239. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Malinowska-Ozdowy K, Frech C, Schönegger
A, Eckert C, Cazzaniga G, Stanulla M, zur Stadt U, Mecklenbräuker
A, Schuster M, Kneidinger D, et al: KRAS and CREBBP mutations: A
relapse-linked malicious liaison in childhood high hyperdiploid
acute lymphoblastic leukemia. Leukemia. 29:1656–1667. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Horton SJ, Giotopoulos G, Yun H, Vohra S,
Sheppard O, Bashford-Rogers R, Rashid M, Clipson A, Chan WI, Sasca
D, et al: Early loss of Crebbp confers malignant stem cell
properties on lymphoid progenitors. Nat Cell Biol. 19:1093–1104.
2017. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao C, Zhang RD, Liu SG, Zhao XX, Cui L,
Yue ZX, Li WJ, Chen ZP, Li ZG, Rao Q, et al: Low CREBBP expression
is associated with adverse long-term outcomes in paediatric acute
lymphoblastic leukaemia. Eur J Haematol. 99:150–159. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chan HM and La Thangue NB: p300/CBP
proteins: HATs for transcriptional bridges and scaffolds. J Cell
Sci. 114:2363–2373. 2001.PubMed/NCBI
|
|
10
|
Yang XJ, Ogryzko VV, Nishikawa J, Howard
BH and Nakatani Y: A p300/CBP-associated factor that competes with
the adenoviral oncoprotein E1A. Nature. 382:319–324. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gorgoulis VG, Zacharatos P, Mariatos G,
Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N,
Kittas C and Papavassiliou AG: Transcription factor E2F-1 acts as a
growth-promoting factor and is associated with adverse prognosis in
non-small cell lung carcinomas. J Pathol. 198:142–156. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
DeGregori J: The genetics of the E2F
family of transcription factors: Shared functions and unique roles.
Biochim Biophys Acta. 1602:131–150. 2002.PubMed/NCBI
|
|
13
|
Ross ME, Zhou X, Song G, Shurtleff SA,
Girtman K, Williams WK, Liu HC, Mahfouz R, Raimondi SC, Lenny N, et
al: Classification of pediatric acute lymphoblastic leukemia by
gene expression profiling. Blood. 102:2951–2959. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li Z, Zhang W, Wu M, Zhu S, Gao C, Sun L,
Zhang R, Qiao N, Xue H, Hu Y, et al: Gene expression-based
classification and regulatory networks of pediatric acute
lymphoblastic leukemia. Blood. 114:4486–4493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu FF, Wang KL, Deng LP, Liu X, Wu MY,
Wang TY, Cui L and Li ZG: Transcription factor E2F3a regulates
CASP8AP2 transcription and enhances sensitivity to chemotherapeutic
drugs in acute lymphoblastic leukemia. Cancer Cell Int. 18:402018.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Konermann S, Brigham MD, Trevino AE, Joung
J, Abudayyeh OO, Barcena C, Hsu PD, Habib N, Gootenberg JS,
Nishimasu H, et al: Genome-scale transcriptional activation by an
engineered CRISPR-Cas9 complex. Nature. 517:583–588. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Huang H, Zou X, Zhong L, Hou Y, Zhou J,
Zhang Z, Xing X and Sun J: CRISPR/dCas9-mediated activation of
multiple endogenous target genes directly converts human foreskin
fibroblasts into Leydig-like cells. J Cell Mol Med. 23:6072–6084.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mei Y, Gao C, Wang K, Cui L, Li W, Zhao X,
Liu F, Wu M, Deng G, Ding W, et al: Effect of microRNA-210 on
prognosis and response to chemotherapeutic drugs in pediatric acute
lymphoblastic leukemia. Cancer Sci. 105:463–472. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Toso C and Lindley C: Vinorelbine: A novel
vinca alkaloid. Am J Health Syst Pharm. 52:1287–1304. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fung MKL and Chan GC: Drug-induced amino
acid deprivation as strategy for cancer therapy. J Hematol Oncol.
10:1442017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Aubel-Sadron G and Londos-Gagliardi D:
Daunorubicin and doxorubicin, anthracycline antibiotics, a
physicochemical and biological review. Biochimie. 66:333–352. 1984.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Al-Aamri HM, Ku H, Irving HR, Tucci J,
Meehan-Andrews T and Bradley C: Time dependent response of
daunorubicin on cytotoxicity, cell cycle and DNA repair in acute
lymphoblastic leukaemia. BMC Cancer. 19:1792019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Frei E III and Sallan SE: Acute
lymphoblastic leukemia: Treatment. Cancer. 42 (2 Suppl):S828–S838.
1978. View Article : Google Scholar
|
|
25
|
Garcia-Carpizo V, Ruiz-Llorente S,
Sarmentero J, Graña-Castro O, Pisano DG and Barrero MJ:
CREBBP/EP300 bromodomains are critical to sustain the GATA1/MYC
regulatory axis in proliferation. Epigenetics Chromatin. 11:302018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ait-Si-Ali S, Polesskaya A, Filleur S,
Ferreira R, Duquet A, Robin P, Vervish A, Trouche D, Cabon F and
Harel-Bellan A: CBP/p300 histone acetyl-transferase activity is
important for the G1/S transition. Oncogene. 19:2430–2437. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dutta R, Tiu B and Sakamoto KM: CBP/p300
acetyltransferase activity in hematologic malignancies. Mol Genet
Metab. 119:37–43. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Trouche D and Kouzarides T: E2F1 and
E1A(12S) have a homologous activation domain regulated by RB and
CBP. Proc Natl Acad Sci USA. 93:1439–1442. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Trouche D, Cook A and Kouzarides T: The
CBP co-activator stimulates E2F1/DP1 activity. Nucleic Acids Res.
24:4139–4145. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang H, Larris B, Peiris TH, Zhang L, Le
Lay J, Gao Y and Greenbaum LE: C/EBPbeta activates E2F-regulated
genes in vivo via recruitment of the coactivator CREB-binding
protein/P300. J Biol Chem. 282:24679–24688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martínez-Balbás MA, Bauer UM, Nielsen SJ,
Brehm A and Kouzarides T: Regulation of E2F1 activity by
acetylation. EMBO J. 19:662–671. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Marzio G, Wagener C, Gutierrez MI,
Cartwright P, Helin K and Giacca M: E2F family members are
differentially regulated by reversible acetylation. J Biol Chem.
275:10887–10892. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Leone G, DeGregori J, Yan Z, Jakoi L,
Ishida S, Williams RS and Nevins JR: E2F3 activity is regulated
during the cell cycle and is required for the induction of S phase.
Genes Dev. 12:2120–2130. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leone G, Nuckolls F, Ishida S, Adams M,
Sears R, Jakoi L, Miron A and Nevins JR: Identification of a novel
E2F3 product suggests a mechanism for determining specificity of
repression by Rb proteins. Mol Cell Biol. 20:3626–3632. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jiao Y, Cui L, Gao C, Li W, Zhao X, Liu S,
Wu M, Deng G and Li Z: CASP8AP2 is a promising prognostic indicator
in pediatric acute lymphoblastic leukemia. Leuk Res. 36:67–71.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Barcaroli D, Bongiorno-Borbone L,
Terrinoni A, Hofmann TG, Rossi M, Knight RA, Matera AG, Melino G
and De Laurenzi V: FLASH is required for histone transcription and
S-phase progression. Proc Natl Acad Sci USA. 103:14808–14812. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
De Cola A, Bongiorno-Borbone L, Bianchi E,
Barcaroli D, Carletti E, Knight RA, Di Ilio C, Melino G, Sette C
and De Laurenzi V: FLASH is essential during early embryogenesis
and cooperates with p73 to regulate histone gene transcription.
Oncogene. 31:573–582. 2012. View Article : Google Scholar : PubMed/NCBI
|
